Today’s pharmaceutical landscape is characterized by drug development programs that routinely span continents, involving distributed research teams, multinational clinical trial…
Read More
Top pharma companies set sustainability goals, but emissions are still increasing
The global healthcare industry stands as a significant contributor to the planet’s carbon footprint, accounting for an estimated 4.4% of…
Read More
Traumatic brain injury and Alzheimer’s disease, common neuroinflammatory pathologies and therapeutic potential
Traumatic Brain Injury (TBI) stands as a formidable global public health crisis, impacting an estimated 69 million individuals annually across…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as significant players in the global pharmaceutical landscape, securing approximately…
Read More
EClinical Solutions Study Models 241% ROI from AI-Powered Clinical Trial Data Platform
A groundbreaking study, commissioned by clinical trial platform company eClinical Solutions and conducted by independent research firm Hobson & Company,…
Read More
Immunai’s Digital ‘Plumbing’ Keeps AstraZeneca Coming Back for Broader, Deeper Collaborations
Immunai, a pioneering startup dedicated to constructing a foundational model of the human immune system, has significantly expanded its strategic…
Read More
A decade in the making: How functional NAMs are redefining cardiac safety assessment
The landscape of drug safety testing is undergoing a profound transformation, marked by the rapid ascent of New Approach Methodologies…
Read More
BioNTech’s Dramatic Pivot: From €19B COVID Vaccine Fortunes to 1,860 Job Cuts and a €16.8B Oncology Bet
The German biotechnology powerhouse BioNTech, once synonymous with its groundbreaking COVID-19 vaccine Comirnaty, is undergoing a profound strategic transformation, shedding…
Read More
Pharma R&D Returns Soar to 7% Driven Almost Exclusively by GLP-1 Therapies, Deloitte Report Reveals
The pharmaceutical industry, after a period characterized by uneven growth and post-pandemic recalibration, is witnessing a significant upturn in R&D…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The Canadian healthcare landscape is poised for a significant transformation with Health Canada’s authorization of Dr. Reddy’s Laboratories’ generic semaglutide…
Read MoreYOU MAY HAVE MISSED
